top of page
Executive Spotlights

Merck to Acquire EyeBio for Up to $3B

Rahway, NJ, and New York, May 29, 2024 (Business Wire) -- Merck is acquiring EyeBio, a biotech company focused on eye diseases, in a deal potentially worth $3 billion. This move strengthens Merck's ophthalmology presence and bolsters its pipeline with promising candidates, including a late-stage drug for macular degeneration expected to enter a pivotal trial later this year.


Read full article here.

Recent Posts

See All

AxoSim appoints Alif Saleh as CEO

New Orleans, LA, June 14, 2024 (Indian Pharma Post) -- AxoSim, a life science firm specializing in lab-grown human brains, has appointed Alif Saleh as its new CEO. Salef, a company builder, brings e

Comments


Life Science Headlines
bottom of page